Corrigendum to ‘Dioscin attenuates renal ischemia/reperfusion injury by inhibiting the TLR4/MyD88 signaling pathway via up-regulation of HSP70′ [Pharmacol. Res. 100 (2015) 341–352]

• Meng Qi,
• Lingli Zheng,
• Yan Qi,
• Xu Han,
• Youwei Xu,
• Lina Xu,
• Lianhong Yin,
• Changyuan Wang,
• Yanyan Zhao,
• Huijun Sun,
• Kexin Liu,
• Jinyong Peng

Affiliations

Meng Qi

College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian 116044, China

Lingli Zheng

Department of Pharmaceuticals, The First Affiliated Hospital of Dalian Medical University, Dalian 116011,China

Yan Qi

College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian 116044, China

Xu Han

College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian 116044, China

Youwei Xu

College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian 116044, China

Lina Xu

College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian 116044, China

Lianhong Yin

College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian 116044, China

Changyuan Wang

College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian 116044, China

Yanyan Zhao

College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian 116044, China

Huijun Sun

College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian 116044, China

Kexin Liu

College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian 116044, China

Jinyong Peng

College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian 116044, China; Corresponding author.